Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation

• Status: Completed
• Trial end date: 2018-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

Currently, there is very little research to identify ways to decrease blood loss during D&E (dilation and evacuation) procedures. The objective is to determine whether routine use of intravenous oxytocin will improve bleeding outcomes at the time of D&E at 18-24-weeks gestation. To evaluate the hypothesis, investigators will perform a randomized, double-blinded, placebo-controlled trial. The patient will be followed until discharged from the postoperative care unit during which time patient satisfaction, pain score and postoperative bleeding will be assessed.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Hawaii
• Collaborators: Society of Family Planning; University of Washington
• Treatments: Oxytocin

Criteria

Inclusion Criteria:

• Requesting pregnancy termination

• Intrauterine pregnancy at 18- to 24-weeks gestation

• Gestational-age to be confirmed by ultrasound

• Patients with fetal anomaly or intrauterine fetal demise that occurred at 18- to 24-weeks gestation

• Willing and able to understand and sign written informed consents in English or Spanish and comply with study procedures

Exclusion Criteria:

• Ultrasound findings suggestive of placenta accreta

• Patients requiring preoperative misoprostol